Drugs / 18F-FET
18F-FET
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07456878 | Jan → Dec 2026 expected | pituitary gland adenoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT05450744 | Apr 2023 → Jun 2026 overdue | glioblastoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07360548 | Sep 2026 → Sep 2030 expected | functioning pituitary gland adenoma | University Hospital, Lille | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04044937 | Oct 2018 → Mar 2024 | brain neoplasm, glioblastoma, grade II glioma, grade III glioma | Thomas Hope | Completed | No outcome recorded |
| Phase 2 | NCT01756352 | Feb 2013 → Sep 2015 | glioblastoma | Marcelo F. Di Carli, MD, FACC | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07475390 | Feb 2026 → Dec 2027 expected | brain glioma | Tomsk National Research Medical Center of the Russian Academy of Sciences | Active not recruiting | No outcome recorded |
| — | NCT07366710 | Nov 2024 → Oct 2027 expected | NAFLD1, glucose metabolism disease | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | \[18F\]FET | “after intravenous administration of 5 mCi ± 0.5 mCi of Fluoroethyl-L-tyrosine (\[18F\]FET)” NCT07456878 ↗4“18F-FET: injection/solution administrated intravenously” NCT05450744 ↗ |
| Known as | 131I-IPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05450744 ↗ |
| Known as | 18FET | “The protocol consists of a single arm involving the administration of the radiopharmaceutical 18FET (IASOglio).” NCT07360548 ↗ |
| Known as | [18F]Fluoroethyl-L-tyrosine | “The experimental drug is \[18F\]Fluoroethyl-L-tyrosine, produced in accordance with Good Manufacturing Practices (GMP) guidelines and marketed under the name IASOglio by Curium...” NCT07360548 ↗ |
| Known as | F-18 Fluoroethyltyrosine (FET) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04044937 ↗ |
| Known as | fluoroethyl-L tyrosine (18F) | “Drug: fluoroethyl-L tyrosine (18F)” NCT07360548 ↗ |
| Known as | Fluoroethyl-L-tyrosine | “after intravenous administration of 5 mCi ± 0.5 mCi of Fluoroethyl-L-tyrosine (\[18F\]FET)” NCT07456878 ↗ |
| Known as | IASOglio | “The experimental drug is \[18F\]Fluoroethyl-L-tyrosine, produced in accordance with Good Manufacturing Practices (GMP) guidelines and marketed under the name IASOglio by Curium...” NCT07360548 ↗ |
| Known as | O-(2-\[18F\]fluoroethyl)-L-tyrosine | “Oral administration of O-(2-\[18F\]fluoroethyl)-L-tyrosine (18F-FET) for total-body PET/CT to assess gastrointestinal amino acid absorption and whole-body amino acid metabolism.” NCT07366710 ↗ |
| Modality | Diagnostic / imaging agent | “The PET radiotracer FET provides a measure of large, neutral amino acid transport.” NCT01756352 ↗ |
| Route | Intravenous | “Participants receive F-18 fluoroethyltyrosine intravenously (IV) over approximately 1 minute” NCT04044937 ↗ |